Jonathan P. Foster - 04 Nov 2025 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
Chief Financial Officer
Signature
/s/ Jonathan P. Foster
Issuer symbol
MBRX
Transactions as of
04 Nov 2025
Net transactions value
-$2,496
Form type
4
Filing time
06 Nov 2025, 20:24:26 UTC
Previous filing
21 Jul 2025
Next filing
14 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Foster Jonathan P. Chief Financial Officer C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON /s/ Jonathan P. Foster 06 Nov 2025 0001545414

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +20,625 +7.2% 308,212 04 Nov 2025 Direct F1
transaction MBRX Common Stock Options Exercise $2,496 -5,023 -1.6% $0.4970 303,189 04 Nov 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -20,625 -2% $0.000000 1,017,695 04 Nov 2025 Common Stock 20,625 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3 On November 4, 2024, the reporting person was granted 82,500 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.